EP3728311A4 - Anticorps bispécifiques neutralisants hiv-1 - Google Patents

Anticorps bispécifiques neutralisants hiv-1 Download PDF

Info

Publication number
EP3728311A4
EP3728311A4 EP18898849.7A EP18898849A EP3728311A4 EP 3728311 A4 EP3728311 A4 EP 3728311A4 EP 18898849 A EP18898849 A EP 18898849A EP 3728311 A4 EP3728311 A4 EP 3728311A4
Authority
EP
European Patent Office
Prior art keywords
neutralizing antibodies
bispecific
hiv
bispecific hiv
neutralizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18898849.7A
Other languages
German (de)
English (en)
Other versions
EP3728311A1 (fr
Inventor
David D. Ho
Yaoxing Huang
Jian Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/850,832 external-priority patent/US10308707B2/en
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of EP3728311A1 publication Critical patent/EP3728311A1/fr
Publication of EP3728311A4 publication Critical patent/EP3728311A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
EP18898849.7A 2017-12-21 2018-12-20 Anticorps bispécifiques neutralisants hiv-1 Pending EP3728311A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/850,832 US10308707B2 (en) 2013-12-02 2017-12-21 Bispecific HIV-1-neutralizing antibodies
PCT/US2018/066643 WO2019135921A1 (fr) 2017-12-21 2018-12-20 Anticorps bispécifiques neutralisants hiv-1

Publications (2)

Publication Number Publication Date
EP3728311A1 EP3728311A1 (fr) 2020-10-28
EP3728311A4 true EP3728311A4 (fr) 2021-11-17

Family

ID=67143961

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18898849.7A Pending EP3728311A4 (fr) 2017-12-21 2018-12-20 Anticorps bispécifiques neutralisants hiv-1

Country Status (7)

Country Link
EP (1) EP3728311A4 (fr)
JP (1) JP7345861B2 (fr)
CN (1) CN111819196B (fr)
AU (1) AU2018399587A1 (fr)
CA (1) CA3085351A1 (fr)
TW (1) TWI745643B (fr)
WO (1) WO2019135921A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
CN117980465A (zh) * 2021-08-30 2024-05-03 康霖生物科技（杭州）有限公司 一种用于艾滋病病毒感染基因治疗的基因序列构建体
WO2024008177A1 (fr) * 2022-07-08 2024-01-11 Nanjing Curegene Technology Co., Ltd. Cellules modifiées et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150152167A1 (en) * 2013-12-02 2015-06-04 Aaron Diamond Aids Research Center Hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014089152A1 (fr) * 2012-12-04 2014-06-12 University Of Maryland, Baltimore Anticorps liant la protéine env du vih-1, protéines de fusion et leurs méthodes d'utilisation
WO2016054023A1 (fr) * 2014-09-29 2016-04-07 Duke University Anticorps anti-vih-1 et utilisations de ceux-ci (adcc et ab bispécifiques)
AU2016347058B2 (en) 2015-10-25 2023-11-09 Sanofi Trispecific and/or trivalent binding proteins for prevention or treatment of HIV infection

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150152167A1 (en) * 2013-12-02 2015-06-04 Aaron Diamond Aids Research Center Hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUANG YAOXING ET AL: "Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity", CELL, ELSEVIER, AMSTERDAM NL, vol. 165, no. 7, 16 June 2016 (2016-06-16), pages 1621 - 1631, XP029612948, ISSN: 0092-8674, DOI: 10.1016/J.CELL.2016.05.024 *

Also Published As

Publication number Publication date
TWI745643B (zh) 2021-11-11
CN111819196B (zh) 2022-10-28
TW201938583A (zh) 2019-10-01
AU2018399587A1 (en) 2020-07-09
JP2021506945A (ja) 2021-02-22
CN111819196A (zh) 2020-10-23
JP7345861B2 (ja) 2023-09-19
EP3728311A1 (fr) 2020-10-28
WO2019135921A1 (fr) 2019-07-11
CA3085351A1 (fr) 2019-07-11

Similar Documents

Publication Publication Date Title
EP3589313A4 (fr) Anticorps anti-tigit
IL279235A (en) DLL3-CD3 bispecific antibodies
EP3569709A4 (fr) Anticorps anti-gpc3
EP3481869A4 (fr) Anticorps anti-cd73
PL3519437T3 (pl) Przeciwciała dwuswoiste przeciwko p95HER2
EP3387442A4 (fr) Anticorps anti-cd73 humanisés
EP3487888A4 (fr) Anticorps anti-her2 bispécifique
EP3334763A4 (fr) Nouveaux anticorps anti-pd-1
EP3661558A4 (fr) Anticorps anti-il1rap
EP3332006A4 (fr) Nouveaux anticorps anti-pd-l1
EP3242894A4 (fr) Anticorps anti-pd-l1
EP3129055A4 (fr) Anticorps anti-her2 bispécifiques
EP3307777A4 (fr) Nouveaux anticorps anti-pd-l1
EP3606961B8 (fr) Anticorps anti-garp-tgf-beta
EP3380524A4 (fr) Anticorps anti-cll-1 humanisés
EP3684806A4 (fr) Nouveaux anticorps anti-cd3epsilon
EP3507307A4 (fr) Anticorps bispécifiques
GB201710838D0 (en) Bispecific antibodies
EP3512885A4 (fr) Anticorps anti-pd-1
EP3763743A4 (fr) Anticorps bispécifique
EP3691447A4 (fr) Anticorps anti-transthyrétine
EP3661555A4 (fr) Anticorps bispécifiques et leurs utilisations
EP3617231A4 (fr) Anticorps anti-gpc-1
EP3526247A4 (fr) Anticorps anti-il1-rap
EP3596126A4 (fr) Nouveaux anticorps anti-trkb

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200708

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036491

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20211014

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 16/32 20060101ALI20211008BHEP

Ipc: A61K 39/00 20060101ALI20211008BHEP

Ipc: A61P 31/18 20060101ALI20211008BHEP

Ipc: C07K 16/28 20060101ALI20211008BHEP

Ipc: C07K 16/18 20060101ALI20211008BHEP

Ipc: C07K 16/10 20060101AFI20211008BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230314

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20230630